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Introduction: Nicotinic acetylcholine receptors are present in the cerebral white matter
(WM). We hypothesized that WM response to nicotine can be detected by diffusion tensor
imaging (DTI); and that such responses may be associated with nicotine-led cognitive
enhancement in sustained attention.
Methods: A randomized, nicotine-placebo patch, crossover, double-blind clinical trial in
two non-overlapping cohorts of smokers was used to test the hypothesis. The discovery
cohort consisted of 39 subjects (N = 20/19 controls/schizophrenic patients, age = 36.8 ±
10.1 years) and the replication cohorts consisted of 38 healthy smokers (31.7 ± 10.5 years).
WM integrity was measured by fractional anisotropy (FA) values for the whole brain and
nine preselected WM tracts using tract-based-spatial-statistics.
Results: Nicotine significantly enhanced FA values for the genu of corpus callosum
compared with placebo (FAgenu) (p = 0.01) in smokers with low recent smoking
exposure as measured by low average cotinine level. This finding was replicated in the
second cohort (p = 0.02). FAgenu values explained 22% of variance in performance of a
sustained attention task during the nicotine session (p = 0.006). However, this effect was
limited to schizophrenia patients (r = 0.62 and 0.09; p = 0.003 and 0.7 for patients and
controls, respectively).
Conclusion: Acute pharmacological influence of nicotine patch on WM integrity appeared
present, but was dependent on nicotine intake from recent smoking. Change in the WM
integrity in the genu of corpus callosum was associated with a significant proportion
of variability of nicotine-led changes in sustained attention/working memory of the
smokers. Further studies will be necessary to understand biophysical underpinning of the
nicotine-related changes in FA.
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INTRODUCTION
Pharmacological effects of nicotine on the central nervous
system are traditionally measured by its impact on synap-
tic terminal nicotinic acetylcholine receptors (nAChRs) located
within gray matter structures. However, PET ligand and his-
tological binding studies have demonstrated that nAChRs are
present in the cerebral white matter (WM) in both human
and non-human primates (Ding et al., 2004; Pimlott et al.,
2004; Kimes et al., 2008; Hillmer et al., 2011). Non-synaptic
nAChRs have been thoroughly studied in the peripheral (Lang
et al., 2003) and central (Zhang et al., 2011a) nervous sys-
tems. Nicotinic agonist applied to the axonal trunks led to
increased axonal excitability, axonal Ca2+ influx (Zhang et al.,
2004), and modulation of action potentials, suggesting these
receptors are functional (Vizi and Lendvai, 1999; Zhang et al.,
2004). Axonal application of nAChR antagonist blocks this effect
(Vizi and Lendvai, 1999), indicating a direct axonal nAChR
functional effect. Here, we employed a standard clinical trial
design to evaluate two hypotheses in humans. First, we hypoth-
esized that an acute pharmacological effect of nicotine may be
observed in cerebral WM using diffusion tensor imaging (DTI).
Second, we hypothesized that the enhancing effects of nico-
tine on cognition may potentially be associated with nicotine-
related changes in the cerebral WM. Nicotine administration is
known to enhance cognition, with improved sustained atten-
tion being one of the most consistent findings, especially in
patients with schizophrenia (Sacco et al., 2005; Hong et al., 2011).
Our analysis included a cohort of patients with schizophrenia
because patients affected with this disorder show both larger sus-
tained attention deficits and nicotine-related cognitive enhance-
ment than normal controls (Levin et al., 1996; Hong et al.,
2011).
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Acute nicotine effects on cerebral WM have previously never
been reported, although substantial literature is available on
examining the effect of chronic smoking and WM changes.
Neuroimaging research in smokers has linked smoking to changes
in Fractional Anisotropy (FA) of water diffusion, which is a sen-
sitive index of WM integrity (Basser, 1994; Ulug et al., 1995;
Conturo et al., 1996; Pierpaoli and Basser, 1996; Kochunov
et al., 2007). Seemingly contradictory effects of smoking on FA
have been observed. Most studies in chronic and heavy smok-
ers reported reduced FA values when compared to non-smokers
(Swan and Lessov-Schlaggar, 2007; Hudkins et al., 2010; Kim
et al., 2010; Cullen et al., 2011; Gons et al., 2011; Liao et al.,
2011; Zhang et al., 2011a,b). However, light smoking and smok-
ing in adolescents have been associated with FA increases when
compared to age and gender matched non-smokers (Paul et al.,
2008; Hudkins et al., 2010; Liao et al., 2011). We propose that
it is possible that shorter exposure to nicotine in the adolescents
(Jacobsen et al., 2007; Cullen et al., 2011) or lighter smoking (Paul
et al., 2008) was associated with increased WM-FA values possi-
bly because nicotine may have a net effect on enhancing FA; while
in more chronic or heavier smokers, nicotine-related FA change





DTI data were collected in 39 adult smokers, including 20 nor-
mal controls (17/3 M/F, age = 36.5 ± 10.5 years) and 19 age and
sex frequency-matched schizophrenia patients (17/2 M/F, age =
37.2 ± 10.9 years) (Table 1), during a clinical trial that studied
nicotine’s effect on cognitive functions under fMRI (Hong et al.,
2011). All subjects were habitual smokers, consuming 19.5 ±
8.2 cigarettes per day (CPD) and with a history of 19.8 ± 16.6
pack/years (Table 1). Normal controls were recruited through
media advertisements. There were no significant patients vs.
controls differences on any of smoking related measurements
(two-tailed t-test p > 0.5). Patients were recruited from local
mental health outpatient clinics. All participants were evaluated
by the Structured Clinical Interview for DSM-IV. Subjects with
current alcohol and/or substance dependence or abuse were
excluded. Schizophrenia patients were clinically stable, medicated
on antipsychotic medication, and had no change in medications
or dosage of their medications between the two DTI sessions
(Table 1). Normal controls had no DSM-IV Axis I diagnosis. All
subjects signed written informed consent approved by local IRB
panels.
Study design
DTI data were evaluated in two sessions during placebo and nico-
tine patch application in a double-blind, randomized, cross-over
design, about 1 week part (Figure 1). Subjects maintained their
usual smoking pattern on each scanning session until about 1 h
prior to the administration of transdermal patch and then wore
the patch and abstained from further smoking for 4.5 h (2.5 h
before + 2 h during imaging). Carbon monoxide (CO) levels
were measured immediately prior to patch applications. Subjects
who smoked greater than 15 CPD received 35mg of nicotine
while those smoking between 10 and 14 CPD received a patch
with 21mg of nicotine (Nicoderm CQ, GlaxoSmithKline, NC),
an approach we used to better approximate the nicotine dose
to smoking severity. The appearance of the placebo patches was
matched to that of the nicotine patches. After patch application,
the subject waited for 2.5 h to achieve steady serum level of nico-
tine. The subject was then positioned in the scanner and under-
went an 8-minute T1 scan and an 8-minute DTI scan, followed by
other behavioral fMRI scans that are described elsewhere (Hong
et al., 2011). DTI data was therefore collected after about 3 h of
nicotine patch or about 4 h from last cigarette smoking.
Immediately following the completion of an imaging session,
venous blood was drawn to measure blood-levels of nicotine
and cotinine. Nicotine exposure from two sources was quanti-
fied: from the acute patch vs. from chronic cigarette smoking
(Hong et al., 2011; Schnoll et al., 2011). The individual nicotine
absorption from the nicotine patch was quantified by subtracting
nicotine levels during the nicotine session from that during the
placebo session. The individual nicotine intake from recent smok-
ing was estimated by averaging the cotinine levels taken from the
Table 1 | Subjects’ demographic and clinical information including gender, age, cotinine level, current antipsychotic medication dose, as
calculated by chlorpromazine equivalent (CPZ), and Fagerstrom Test for Nicotine Dependence (FTND) scores, a measure of smoking addiction
severity.
Discovery cohort Replication cohort
Whole sample Low cotinine High cotinine p-value Whole sample Low cotinine High cotinine p-value
Subjects (M/F) 39 (34/5) 17 (15/2)* 17 (14/3)* 0.6 38 (18/20) 19 (10/9) 19 (8/11) 0.5
Cotinine (±sd) 321.7 ± 143.1 208.1 ± 77.4 428.4 ± 94.4 1.00E-08 283.2 ± 102.0 194.9 ± 94.1 363.6 ± 73.5 2.00E-07
Age (±sd) 37.1 ± 10.6 39.1 ± 10.8 35.2 ± 10.4 0.32 31.8 ± 7.6 31.6 ± 7.3 31.9 ± 8.1 0.9
Patients/controls 19/20 7/10* 10/7* 0.4 N/A N/A N/A N/A
CPZ (±sd) 397.4 ± 237.8 427.4 ± 263.8 379.2 ± 233.6 0.7 N/A N/A N/A N/A
FTND (±sd) 4.6 ± 2.1 3.8 ± 2.2 5.4 ± 1.7 0.005 5.9 ± 2.3 5.1 ± 1.9 6.8 ± 2.3 0.02
Pack years (±sd) 19.8 ± 16.6 19.0 ± 15.1 21.2 ± 18.4 0.7 15.2 ± 9.7 13.9 ± 7.6 16.6 ± 11.6 0.4
The two cohorts were further subdivided into high and low average cotinine groups. P-values were from two-tailed t-test or χ2 test, to evaluate difference between
high and low cotinine subgroups. *Average cotinine measurements were available for 34 subjects in the first sample, including 17 patients and 17 controls.
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FIGURE 1 | Schematic diagram of the clinical trial procedure for the
discovery sample. The procedure for the replication sample was
essentially the same, but without the RVIP fMRI.
2 sessions. This is because nicotine has a short half-life (∼60min)
and therefore its serum level is a sensitive measurement of short-
term nicotine exposure. Cotinine level was used to quantify
recent nicotine exposure from smoking (Schnoll et al., 2011).
Cotinine has a long half-life (∼20 h) and its levels will there-
fore be more sensitive to recent cumulative nicotine intake from
smoking rather than from patch absorption. Nicotine measure-
ments for six subjects and cotinine measurements for five subjects
were not available due to various technical problems. To monitor
side effects and withdrawal symptoms, a self-reported symptom
checklist and a self-reported mood change questionnaire (Parrott
et al., 1996) were administered before patch application and
after scan.
Imaging
Imaging data was collected using a Siemens 3T Allegra MRI
(Erlangen, Germany) located at the National Institute on Drug
Abuse (NIDA), NIH using a quadrature RF head coil. DTI data
was collected using a spin-echo, EPI sequence with a spatial res-
olution of 1.7 × 1.7 × 4.0mm. The sequence parameters were:
TE/TR = 87/5000ms, FOV = 200mm, axial slice orientation
with 35 slices and no gaps, twelve isotropically distributed dif-
fusion weighted directions, two diffusion weighting values (b = 0
and 1000 s/mm2) and one b = 0 image. Five set of images were
collected for the subsequent averaging to improve signal to noise.
Subjects’ head movement was minimized by the use of foam
padding, a vacuum bag, bite bar, and/or hardened polyurethane
foam.
Processing of DTI data
A tract-based spatial statistics (TBSS) method, distributed as a
part of FMRIB Software Library (FSL) package, was used for
tract-based analysis of diffusion anisotropy (Smith et al., 2006).
First, FA images were created by fitting the diffusion tensor to
the raw diffusion data. In the next step, all FA images were
globally spatially normalized to the John Hopkins University
(JHU) that is distributed with the FSL package (Wakana et al.,
2004) and then non-linearly aligned to a group-wise, minimal-
deformation target (MDT) brain as detailed elsewhere (Jahanshad
et al., 2013). The global spatial normalized was performed using
a method distributed with FSL package (FLIRT) (Smith et al.,
2006) with 12◦ of freedom. This step was performed to reduce
the global intersubject variability in brain volumes prior to non-
linear alignment. The group’s MDT brain is identified by warping
all individual brain images in the group to each (Kochunov
et al., 2001). The MDT is selected as the image that minimizes
the amount of the required deformation from other images in
the group. Next, individual FA images are averaged to produce
a group-average anisotropy image. This image is used to create a
group-wise skeleton of WM tracts. The skeletonization procedure
is a morphological operation, which extracts the medial axis of an
object. This procedure is used to encode the medial trajectory of
the WM fiber-tracts with one-voxel thin sheaths.
Finally, FA images were thresholded at FA = 0.20 level to elim-
inate non-WM voxels and FA values were projected onto the
group-wise skeleton of WM structures. This step accounts for
residual misalignment among individual WM tracts. FA values
are assigned to each point along a skeleton using the peak value
found within a designated range perpendicular to the skeleton.
The FA values vary rapidly perpendicular to the tract direction
but very slowly along the tract direction. By assigning the peak
value to the skeleton, this procedure effectively maps the center
of individual WM tracts on the skeleton. This processing is per-
formed under two constraints. A distance map is used to establish
search borders for individual tracts. The borders are created by
equally dividing the distance between two nearby tracts. Secondly,
a multiplicative 20mm full width at half-max Gaussian weighting
is applied during the search to limitmaximumprojection distance
from the skeleton. Beside FA, we also explored radial and axial
diffusivity.
Estimation of intra-session motion
Average head motion during the DTI scans were measured by
spatial alignment of diffusion-sensitized (b = 1000) images to
the b = 0 image. Automated, nine-parameter (three rotations,
three scales, and three translations) FLIRT spatial normaliza-
tion method was used with default parameters. Next, RMSDIFF
(Smith et al., 2004) was used to estimate the root mean square
(RMS) movement distance between diffusion sensitized and b =
0 images. The RMSDIFF program calculates the RMS difference
in transformed locations using a simple spherical brain model
that spanned 25% of the space. The 4 × 4 alignment matri-
ces for diffusion-sensitized images were compared to a 4 × 4
identity matrix, which served as the no-movement reference.
The RMS distance calculation accounted both translation and
rotation providing a sensitive index of head motion.
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Tract-based analysis
To explore tract-specific effect, the population-based, 3D, DTI
cerebral WM tract atlas developed in John Hopkins University
(JHU) and distributed with the FSL package (Wakana et al., 2004)
was used to calculate population average FA values along the spa-
tial course of nine, largest, core WM tracts (Table 2, Figure 2) as
described elsewhere(Kochunov et al., 2010, 2011a). These tracts
were chosen based on their size (>10 cm3) and their presence
in all subjects, which simplifies multi-subject analysis (Wakana
et al., 2004; Kochunov et al., 2011b). The details of the by-tract
measurements are detailed elsewhere (Jahanshad et al., 2013).
Per-tract average values were calculated by averaging the values
along the tracts in both hemispheres as detailed in our prior work
(Kochunov et al., 2011b; Jahanshad et al., 2013). The overall aver-
age FA values were calculated by averaging values for the entire
WM skeleton.
Table 2 | White matter tracts used in the analysis.
Tract Fiber type Connections
Genu, body, and splenium
of corpus callosum
C Cerebral hemispheres
Cingulum (Cing) A Cingulate gyrus/Hippocampus
Corona radiata (CR) P Cortical/Subcortical











C, Commissural; P, Projection; A, Association.
Sustained attention
After DTI and T1 MPRAGE acquisition, a rapid visual informa-
tion processing task (RVIP) was administrated to examine the
effect of nicotine on sustained attention. The RVIP is a contin-
uous performance task (CPT) with a predominantly sustained
attention component and working memory load (Wesnes and
Warburton, 1983). Briefly, we showed (Hong et al., 2011) that
administration of nicotine enhanced accuracy (p = 0.001) and
processing speed (p = 0.03) compared to placebo in schizophre-
nia patients and also enhanced accuracy (p = 0.05) but not
processing speed (p = 0.11) compared with placebo in healthy
controls, but there was no significant treatment × diagnosis
interaction.
Statistical analysis
Significance of treatment effect (nicotine vs. placebo) was calcu-
lated using a paired t-test. Intersession differences in FA values
were calculated as the percent change over the average for both
sessions. Significance of the predictors on the intersession differ-
ences in FA values was assessed using linear correlation analysis.
The above was calculated for the whole brain and for the tract-
specific analyses. Finally, effects of nicotine administration on
cerebral WM integrity were studied using a repeated measure
ANOVA where FA values in the nicotine and placebo condi-
tions were treated the repeated measures. Significant values were
corrected for ten comparisons for whole brain + nine tracts
(p = 0.05/10 = 0.005).
Replication cohort
Significant FA findings from the discovery sample were tested in
a separate, non-overlapping cohort of 38 healthy smokers (18/20
M/F, age= 31.7 ± 10.5 years) (Table 1). All subjects were habitual
smokers, consuming 20.9 ± 6.6 CPD, which was not statistically
different from the discovery cohorts (p = 0.7). Subjects for the
replication cohort were recruited through media advertisements.
FIGURE 2 | Average DTI FA values were measured for ten major cerebral WM tracts (Table 1).
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The study design closely matched that in the discovery cohort;
however, a 21mg nicotine patch was used in all subjects. The DTI
data were collected on the same scanner and the head coil but
using a different version DTI sequence. The same sequence con-
trol parameters were used with exception that one fewer (4 vs. 5)
set of images was collected for averaging. DTI data processing
was the same as in the replication cohort. Statistical analyses in
this cohort were aimed at replication of the significant findings
identified in the discovery cohort.
RESULTS
DISCOVERY COHORT
No diagnosis-by-treatment interactions were found in imaging or
nicotine related measures (all p > 0.20), therefore, schizophre-
nia patients and controls were combined. There was an 8-fold
increase in serum nicotine concentration in the nicotine vs.
placebo sessions (35.2 ± 11.6 vs. 4.1 ± 4.4 ng/ml, respectively;
paired t-test p < 1 × 10−10). The serum cotinine levels were
35% higher during the nicotine than during the placebo ses-
sions (361.2 ± 141.6 vs. 267.9 ± 135.9 units/ml, respectively; p =
0.01). Cotinine levels for two visits were highly correlated (r =
0.75; p < 1 × 10−7) despite the 8-fold difference in nicotine lev-
els, suggesting that this measurement primarily quantifies recent
cumulative nicotine exposure from smoking rather than acute
nicotine from the patch. Therefore, the cotinine levels were aver-
aged to produce a single index of recent cumulative nicotine expo-
sure from smoking. Whole-brain average diffusion parameters
demonstrated excellent (r2 > 0.9) intersession reproducibility.
The highest reproducibility was observed for the axial diffusiv-
ity (r2 = 0.95) and the lowest was seen for the FA values (r2 =
0.92). Intersession reproducibility for the FA values in the genu of
corpus callosum were likewise high for both the discovery and
replication cohorts (r2 = 0.93, 0.90 and.85 for axial and radial
diffusivities and FA, respectively).
Correlation between the average cotinine level and FA
(nicotine vs. placebo) in the whole brain and the nine WM
tracts showed that FA change at the genu of corpus callosum
(FAgenu) from placebo to nicotine patch was significantly cor-
related with average cotinine level (p < 0.001; Table 3), which
was the only significant finding after corrected for N = 10 com-
parisons. None of the correlation between Nicotine and FA
in the whole brain or the nine WM tracts was significant after
correction of multiple comparisons. A repeated measure ANOVA
using genu FA in the nicotine and placebo conditions as the
repeated measures and the average cotinine level was the covari-
ate (Figure 3, left) reported that both the main effect of treatment
and treatment × cotinine interaction were significant (F = 8.9,
p = 0.005 and F = 11.6, p = 0.002, respectively; Greenhouse–
Geisser corrected). To examine the significant interaction, we
divided subjects into high-and-low cotinine groups, consisting
of 17 subjects each, using median split of the averaged coti-
nine (Table 1, Figure 3). Using median split of cotinine levels
for either of the visits resulted in the same group constitution.
Nicotine enhanced the FA at the genu in subjects in the low-
cotinine group (two tailed, paired t-test, p = 0.01)but not in the
high-cotinine group (two tailed, paired t-test p ≈ 0.9). Therefore,
nicotine enhanced FA only when the smokers’ baseline level of
cotinine was low; and this effect was not present when cotinine
level was high.
Change in self-reported withdrawal symptoms was not signif-
icantly different between sessions (6.9 ± 0.7 vs. 7.1 ± 0.8, paired
t-test p-value = 0.25 for nicotine and placebo sessions, respec-
tively) and were not significantly correlated with whole-brain or
by-tract FA (all p > 0.3). Patients and controls showed no dif-
ference in the severity of withdrawal symptoms (p = 0.5). Systolic
blood pressure (BP) was elevated from the placebo to the nicotine
session (126 ± 13.6 vs. 135.6 ± 13.8mmHg, respectively; p =
FIGURE 3 | Treatment effect on FA values for the genu of corpus
callosum by comparing placebo (black bar) and nicotine (gray bars)
showed a significant interaction with average cotinine level in the
discovery cohort (A). Subjects in the discovery cohort were separated into
two (low and high cotinine) equal groups by sorting the data based on
cotinine levels, with the average cotinine levels = 208 ± 77 and
428 ± 94mg/ml, respectively. Nicotine enhanced the FA in the low-cotinine
group (p = 0.01) but not in the high-cotinine group. (B) The low and high
cotinine groups in the replication cohort had average cotinine levels =
194 ± 49 and 364 ± 73mg/ml, respectively. Note that the discovery and
replication cohorts were collected under different DTI protocols, leading to
a systematic difference in the average FA values.
Table 3 | Correlation coefficients for the whole-brain and tract-wise FA value and nicotine and average cotinine levels for the discovery
cohort.
FA Whole Brain Genu Body Splenium Cing CR EC IC SFO and IFO SLF
Nicotine −0.29 (0.10) 0.28 (0.12) 0.16 (0.4) 0.26 (0.14) −0.42 (0.01)* −0.36 (0.04)* 21 (0.2) −0.23 (0.16) −0.21 (0.2) −0.24 (0.2)
(N = 33)
Average cotinine −0.12 (0.5) −0.59 (0.0001)** 0.01 (0.9) 0.18 (0.3) −0.12 (0.5) 0.12 (0.5) −0.01 (0.9) −0.02 (0.8) 0.02 (0.9) 0.04 (0.8)
(N = 34)
*Nominally significant. **Significant after correction for N = 10 comparisons.
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0.005); but not for diastolic BP (p = 0.11). There were no signifi-
cant correlations between FA and BP (p > 0.2). The subjects’
motion averaged 0.66mm during nicotine and 0.65mm during
placebo sessions (paired t-test p = 0.60) and the expected effects
of this motion on FA values are < 0.1% (Muller et al., 2011).
Therefore, there were no significant differences in head motion
between sessions or more importantly, head motion contribution
to the FA findings.
REPLICATION COHORT
There was a 7-fold increase in serum nicotine concentra-
tion in the nicotine vs. placebo sessions (33.6 ± 8.4 vs. 5.0 ±
4.1 ng/ml, respectively; paired t-test p < 1 × 10−10). The serum
cotinine levels were 33% higher during the nicotine than dur-
ing the placebo sessions (320.2 ± 114.9 vs. 241.2 ± 94.3 units/ml,
units/ml, respectively; p = 1 × 10−4). Cotinine levels measured
at the placebo and nicotine were as highly correlated (r =
0.78, p < 1 × 10−7) as in the discovery cohort (r = 0.75). The
nicotine-related parameters were similar to that of the discovery
cohort with no significant differences in the nicotine and aver-
age cotinine levels between two cohorts (nicotine: 31.6 ± 11.7
vs. 29.8 ± 8.34 ng/ml; average cotinine: 321.7 ± 143.1 vs. 283.2 ±
102.1 units/ml, for discovery and replication cohorts, respectively,
all p > 0.2). The correlation between average cotinine levels and
FAgenu was again significant (r = −0.39, p = 0.02). Significant
main effects of treatment and treatment × cotinine interaction
were also observed in the replication cohort (F = 9.1, p = 0.005
and F = 6.2, p = 0.02). The FAgenu values in smokers with
low-cotinine level was significantly higher during nicotine then
in placebo sessions (two tailed, paired t-test, p = 0.02; Table 1,
Figure 3) and this effect was absent in smokers with high average
cotinine level (two tailed, paired t-test p ≈ 0.9).
FA CHANGE AND SUSTAINED ATTENTION
The hypothesis that nicotine-led change in WM integrity is asso-
ciated with enhancement in cognition was tested by correlating
FAgenu with RVIP hit rate and reaction time. Both measures
are enhanced by nicotine (Hong et al., 2011). The hit rate in
the nicotine condition was significantly correlated with FAgenu
(r = 0.44, p = 0.005) (Table 4), significant after Bonferroni cor-
rection for N = 6 comparisons. Additionally, FAgenu was cor-
related with the intersession difference in the reaction time in
the controls (r = 0.32, p = 0.03), although this was not signifi-
cant after Bonferroni correction. In both instances, increases in
WM integrity during nicotine session corresponded to enhanced
performance. A post-hoc analysis showed that the relationship
between FAgenu and hit rate was more pronounced in the
schizophrenia patients (r = 0.62; p = 0.003) than in the normal
controls (r = 0.09; p = 0.7) (Figure 4). We evaluated if either
placebo or nicotine session measures of withdrawal symptoms,
systolic and diastolic BP and motion or their intersession dif-
ference could be associated with cognitive enhancement but
observed no significant correlations between them and RVIP hit
rate and reaction time, or their intersession differences (all r <
0.10, all p > 0.5). Additionally, there were no significant relation-
ships between the dose of antipsychotic medication and neurobe-
havioral performance measurements (all r-values <0.15; all p >
0.4) (Hong et al., 2011). Nicotine related changes inFAgenu were
mainly driven by changes in radial diffusivity, which also demon-
strated significant correlation with the hit rate in the nicotine
condition (r = 0.45, p = 0.004).
DISCUSSION
Our study demonstrated that a subtle change in FA values for the
genu of corpus callosum (FAgenu) between nicotine and placebo
patch sessions had unexpectedly interacted with the average coti-
nine levels, a measure of recent nicotine intake and its metabolism
from cigarette smoking (Schnoll et al., 2011). Subjects with lower
serum cotinine level experienced a significant increase in FAgenu
values due to administration of a single dose of nicotine when
compared with placebo and subjects with high serum cotinine
level experienced no change in FAgenu values. The interpretation
of this finding is not straightforward without the knowledge of
the underlying pharmacological mechanisms but it was replica-
ble in an independent sample and was not associated with head
FIGURE 4 | Nicotine-related changes in FA values of the genu of corpus
callosum (FAGenu) are plotted against the hit rate during nicotine
session, separately in schizophrenia patients (solid point/line) and
normal controls (hollow points/dashed line).
Table 4 | Correlation coefficients for intersession difference in FA values for the genu and corpus callosum and measurements of sustained
attention and reaction time.
Hit rate nicotine Hit rate placebo Hit rate Reaction time Reaction time Reaction time
patch patch nicotine patch placebo patch
FAGenu (N = 38) 0.44 (0.006)** 0.29 (0.08) 0.17 (0.30) −0.24 (0.15) −0.22 (0.20) 0.35 (0.03)*
: Difference between nicotine and placebo patch sessions *Nominally significant. **Only the correlation with hit rate during the nicotine patch session was
considered statistically significant after correction for six comparisons.
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motion, blood pressure, and/or withdrawal symptoms experi-
enced by the subjects. Further, the FAgenu was significantly and
positively correlated with sustained attention performance dur-
ing nicotine patch administration but this finding was observed
only in schizophrenia patients. To our knowledge, this is the first
study to demonstrate and replicate acute pharmacological effects
of nicotine on cerebralWM. This study is also the first demonstra-
tion that an acute pharmacological effect on WM integrity can be
associated with changes in cognitive performance.
The biophysical mechanisms behind the observed effects are
unknown. The absolute FA values are sensitive to many param-
eters including myelin content, intra-voxel axonal crossing and
axonal fiber density and diameter (Beaulieu, 2002). However,
recent work from our group, based on theoretical modeling of
diffusion properties by Sukstanskii et al. (2003, 2004), led to a
development of a permeability-diffusity model of diffusion signal
(Kochunov et al., 2013). There, we showed that the permeability-
diffusivity index, a measurement that is theoretically sensitive to
permeability of cellular membrane, yielded more robust patient-
control differences in schizophrenia than FA values (Kochunov
et al., 2013). Moreover, this work showed that FA values were
significantly correlated with PDI suggesting that FA may in part
be sensitive to the activity of axonal ion-channels. This is consis-
tent with observations made in animal models of ischemic stroke.
Under normal physiological condition, the axonal membranes are
semi-permeable by the active exchange via ionic and water pumps
(Baslow, 2002). Ischemia leads to failure of molecular pumps and
restriction of active permeability. This failure of molecular pumps
is observed as a rapid (within minutes) drop in both radial and
axial diffusivity and the eventual drop in FA (20–50%) (Li et al.,
2000). Here, we speculate that nicotine-related changes in FA val-
ues may be driven by changes in active axonal permeability due to
pharmacological stimulation of nAChRs located within cerebral
WM (Anderson et al., 1996; Mandl et al., 2008). For example,
nAChR α5, α3, and β4 are expressed in unmyelinated human C
fibers (Benarroch and Low, 1991; Lang et al., 2003); and α4β2 and
α7 are expressed in optical nerve axons. Human PET (Ding et al.,
2004) and postmortem human brain ligand binding studies show
unequivocal WM presence of nAChRs (Pimlott et al., 2004).
This potential mechanism of nicotine-related FA change due
to changes in axonal permeability is also supported by the evi-
dence that axonal nAChRs regulate calcium influx (Edwards and
Cline, 1999). Nicotine applied directly to rodent optic nerve axons
increases intra-axonal calcium (Zhang et al., 2004). The axonal
nAChR induced calcium transients have a sustained effect in
modulating action potentials passing through the axons (Zhang
et al., 2004), providing a plausible mechanism to modulate cogni-
tive performance. Alternatively, nicotine effect on FA may also be
due to nicotine stimulation of the nAChRs located at the synaptic
terminals. Finally, nAChRs are also widely expressed in oligo-
dendrocytes and astroglial cells of cerebral WM (Hassel et al.,
2008). Stimulation of glial nAChR inhibits glycogen synthase
kinase 3 (GSK3) and activates Akt/GSK3 myelination pathway
(Bartzokis, 2012), (Flores et al., 2008; Narayanan et al., 2009) and
this may also contribute the observed FA effect. These or other,
yet unidentified, mechanisms may also contribute to the corre-
lation between FA change and cognition. The exact mechanism
cannot be ascertained here, but this finding should encourage
future research to examine how changes in WM integrity may or
may not contribute to the overall nicotine effects on brain and
cognition.
Nicotine is known to improve sustained attention (Levin et al.,
1996; Dépatie et al., 2002; Smith et al., 2002; Harris et al.,
2004; Sacco et al., 2005; Barr et al., 2008). Previous study from
our group demonstrated that nicotine improved accuracy and
reaction time, especially in schizophrenia patients (Hong et al.,
2011). Using the DTI approach, the nicotine effect on genu
FA is now observed to correlate with sustained attention per-
formance, explaining 22% of the variance in hit rate during
the nicotine administration. It is important to emphasize that
the relationship should not be interpreted as causative, predic-
tive, or modulatory. It is fundamentally a correlational finding
that may or may not be causally related. This said, the pat-
tern of correlation suggests that subjects with a higher FAgenu
show a proportionally higher sustained attention in schizophrenia
patients. There FAgenu explained 40% of the sustained atten-
tion variance during nicotine administration. In normal controls
this trend was positive but not significant. The observation that
the robust effect of the change in FA of genu on processing is
meaningful because the genu makes up the majority of fibers for
pre-frontal and frontal inter-hemispheric signal traffic (Aboitiz
et al., 1992). These commissural fibers facilitate inter-hemispheric
connectivity and are thought to modulate the speed of process-
ing of cognitive information (Pfefferbaum et al., 2000; Kochunov
et al., 2009; Salthouse, 2009). The nominally significant correla-
tion between FAgenu and reaction time (RT) (p = 0.03) may
support this notion. It is possible that the micro-architectural
nature of the genu, such as the presence of densely packed, thinly
myelinated fibers (Aboitiz et al., 1992), is what leads to large
FA changes in response to the acute pharmacological effects of
nicotine.
The finding of significantly higher effect of FAgenu on cog-
nition in schizophrenia patients is consistent with the findings
that administration of nicotine in patients significantly improved
(p < 0.001) their performance, while the nicotine-related change
in normal controls was only nominally significant (p = 0.05)
(Hong et al., 2011). Additionally, schizophrenia patients showed
a significantly lower (p < 0.0001) performance on the sustained
attention task during placebo session thereby setting a lower
baseline (Hong et al., 2011). We did not observe a significant cor-
relation between FAgenu and the hit rate during the placebo
condition, however, this correlation was nominally significant
(r = 0.37, p = 0.02) for the change in radial diffusity (Table 5).
The relationship between FAgenu and the enhancement of the
sustained attention task may be difficult to interpret in smokers
because the placebo session may not be measuring the cognitive
baseline as the smokers could experience subtle withdrawal effects
that may confounds their performance (Hendricks et al., 2006).
Re-testing this effect in non-smokers may be critical to improve
the credence to this observation.
Our observations have several limitations. The samples were
heterogeneous in terms of diagnosis, medication exposure,
demographics and duration and severity of smoking exposure,
although our observations were based on within-subject design
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Table 5 | Correlation coefficients for intersession difference in diffusivity values for the genu of corpus callosum and sustained attention hit
rate and reaction time.
Hit rate nicotine Hit rate placebo Hit rate Reaction time Reaction time Reaction time
patch patch nicotine patch placebo patch
L‖genu 0.01 (0.99) −0.17 (0.30) 0.34 (0.05)* 0.28 (0.09) −0.20 (0.23) 0.00 (1.0)
 L⊥genu 0.46 (0.004)** 0.37 (0.02)* 0.01 (0.99) −0.23 (0.15) −0.33 (0.20) 0.24 (0.15)
*Nominally significant. **Only the correlation with hit rate during the nicotine patch session was considered statistically significant after correction for N = 12
comparisons.
where these factors were unchanged. The discovery cohort con-
sisted of schizophrenia patients and controls. However, there were
no difference in the group’s main effect and interaction. Post-hoc
analysis in the discovery cohorts that was performed in nor-
mal controls replicated both the main effect of treatment and
treatment × cotinine interaction (p = 0.02 and p = 0.01, respec-
tively). Subjects in the discovery cohorts received 35 and 21mg
patches, based on their smoking habits, while all subjects in the
replication cohort received 21mg patch. The sample sizes were
small to detect the more subtle pharmacological effects on DTI.
The heterogeneous nature of the samples, especially the discov-
ery sample, could have contributed to several observations unable
to pass the corrections for multiple comparisons. We attempted
to evaluate whether withdrawal symptoms, head motion and
physiological measurements, such as the blood pressure, may
have contributed to the main findings but none of these mea-
sures demonstrated to be significant predictors. However, subtle
withdrawal symptoms, not detectable by the withdrawal scale,
may still have produced measurable changes in sustained atten-
tion (Hendricks et al., 2006). Another potential limitation of this
study is the use of cotinine level as predictors of nicotine intake
from smoking because it is impacted by the treatment during
the nicotine session. We believe this to be a minor limitation
because long metabolic half life of cotinine makes it more sen-
sitive to nicotine intake from smoking rather than the patch.
This is demonstrated by high and consistent inter-session corre-
lation in cotinine levels observed for both cohorts. Nonetheless,
replication of this observation in non-smokers will be necessary
to clarify this. Another limitation was that the DTI protocol
only had 12 directions resulting in limited angular resolution
compared to more modern high-angular resolution diffusion
imaging (HARDI) protocols. This limitation was due to the
use of an older MRI scanner that lacked the HARDI capabil-
ity. We consider this to be a minor limitation since calculation
of FA requires only six non-collinear directions. Use of lower
angular direction protocols leads to lower signal-to-noise ratio
in FA maps (Jones et al., 1999). We attempted to compensate
for it by performing multiple averages (5 and 4 for discov-
ery and replication cohorts, respectively). In conclusion, our
observation remains novel and biologically based. The nicotine
effect on FA can potentially be explained by pharmacological
effects on axonal or glial or synaptic nAChRs that transiently
alter ion concentration in or around the axonal pace to sub-
tly influence WM integrity. Overall, this study should encourage
and help with planning the future research to study the nico-
tine effects on brain and cognition. Specifically, evaluation of
nicotine effects on WM integrity in non-smokers could remove
confounds of past nicotine exposure and improve our under-
standing of biological mechanisms behinds the changes in FA
values.
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